Aurobindo Pharma released the final voting results for its 39th Annual General Meeting (AGM) held on August 27, 2026, confirming that all proposed resolutions were passed with the requisite majority. The company’s shareholders approved the adoption of audited standalone and consolidated financial statements for FY26 and confirmed an interim dividend of ₹4 per equity share.

The total paid-up equity share capital stood at ₹57,53,77,895, comprising 57,53,77,895 fully paid-up equity shares of face value ₹1 each as on the cut-off date of August 20, 2026. A total of 1,243 members participated in the e-voting process, with 1,233 voting remotely and 10 participating via Insta Poll during the virtual meeting.

Voting Results Overview

All six resolutions put forward at the AGM received approval. The voting patterns revealed near-unanimous support for financial statement adoptions and the dividend confirmation. However, the reappointment of key board members saw varying levels of dissent from public institutional investors.

Board Appointments and Dissent Analysis

The reappointment of Mr. K. Nithyananda Reddy, Vice Chairman & Managing Director, who retires by rotation, passed with 94.13% support. However, it recorded the highest dissent among all resolutions, with 5.87% of votes polled against the move. This opposition was concentrated among public institutional shareholders, who voted against the resolution at a rate of 14.22%. Non-institutional public shareholders showed stronger support, with only 0.27% voting against.

Dr. M. Madan Mohan Reddy, Whole-time Director, was also reappointed by rotation. His resolution passed with 98.94% support, facing 1.06% dissent. Public institutions voted against his reappointment at a rate of 2.56%, while non-institutional shareholders opposed it by just 0.27%.

Financial Statements and Dividend

Shareholders overwhelmingly supported the adoption of the audited financial statements for the fiscal year ended March 31, 2026. Both the standalone and consolidated statement resolutions received 99.92% affirmative votes. The slight dissent (0.08%) came primarily from public institutional voters.

The interim dividend of ₹4 per equity share for FY26 was confirmed with near-unanimous approval, garnering 99.99% of votes in favour. Only 12,166 votes were cast against this resolution, representing less than 0.01% of the total votes polled.

Meeting Proceedings

The AGM was conducted via Video Conferencing (VC) / Other Audio Visual Means (OAVM) in compliance with the Companies Act, 2013, and SEBI Listing Regulations. Mr. M.R. Kumar, Chairman of the Board, presided over the meeting. Remote e-voting commenced on August 24, 2026, and concluded on August 26, 2026. The consolidated voting results and Scrutinizer's report, prepared by Mr. Y. Ravi Prasada Reddy of RPR & Associates, have been submitted to the National Stock Exchange of India and BSE Limited.

Aurobindo Pharma will participate in the Goldman Sachs Asia Leaders Conference in Hong Kong on September 1-2, 2026. Company officials are scheduled for one-on-one and group meetings with investors and analysts.

The event runs from 9:00 am to 5:00 pm (HKT) daily. Aurobindo Pharma stated that no unpublished price-sensitive information (UPSI) is intended to be discussed during these interactions.

Meeting Details

The schedule remains subject to change due to exigencies on the part of the investor or the company. B. Adi Reddy, Company Secretary, signed the disclosure dated August 25, 2026.